Results 21 to 30 of about 11,405 (213)

FB-BEV: BEV Representation from Forward-Backward View Transformations

2023 IEEE/CVF International Conference on Computer Vision (ICCV), 2023
Accept to ICCV 2023, camera-ready ...
Zhiqi Li, Zhiding Yu, Wenhai Wang, Anima Anandkumar, Tong Lu 0002, José M. Álvarez 0004   +5 more
openaire   +2 more sources

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma

Cancer Medicine, 2021
Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited.
Masahiro Nishikawa, Akihiro Inoue, Takanori Ohnishi, Hajime Yano, Yonehiro Kanemura, Shohei Kohno, Shiro Ohue, Saya Ozaki, Shirabe Matsumoto, Satoshi Suehiro, Yawara Nakamura, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Takeharu Kunieda   +15 more
doaj   +1 more source

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

BMC Cancer, 2020
Background It is not known what combination of bevacizumab and chemotherapy agents is the best therapeutic regimen. Comparative study results among the efficacies of bevacizumab plus chemotherapy remain controversial in patients with HER2-negative ...
Zhengwu Sun, Xiaoyan Lan, Shizhao Xu, Shen Li, Yalin Xi   +4 more
doaj   +1 more source

The impact of parental death on the timing of first marriage: Evolutionary versus social explanations (The Netherlands, 1850-1940)

Demographic Research, 2019
Background: This article examines the impact of parental death in childhood, adolescence, and adulthood on male and female age at marriage in the Netherlands in the period 1850-1940.
Matthias Rosenbaum-Feldbrügge, Enrico Debiasi   +1 more
doaj   +1 more source

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

BMC Cancer, 2023
Background Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise in extending progression-free survival (PFS) treating GBM, there is no ...
Minjie Fu, Zhirui Zhou, Xiao Huang, Zhenchao Chen, Licheng Zhang, Jinsen Zhang, Wei Hua, Ying Mao   +7 more
doaj   +1 more source

Simple-BEV: What Really Matters for Multi-Sensor BEV Perception?

2023 IEEE International Conference on Robotics and Automation (ICRA), 2023
Building 3D perception systems for autonomous vehicles that do not rely on high-density LiDAR is a critical research problem because of the expense of LiDAR systems compared to cameras and other sensors. Recent research has developed a variety of camera-only methods, where features are differentiably "lifted" from the multi-camera images onto the 2D ...
Adam W. Harley, Zhaoyuan Fang, Jie Li 0031, Rares Ambrus, Katerina Fragkiadaki   +4 more
openaire   +2 more sources

To Bev or Not to Bev during Ovarian Cancer Maintenance Therapy?

Cancers, 2023
Background: Maintenance therapy with PARP inhibitors and bevacizumab is approved for ovarian cancer treatment in the first and second line settings, but selecting the optimal sequence is challenging due to restrictions on using the same medication twice.
openaire   +2 more sources

Establishment and application of multiplex droplet digital polymerase chain reaction assay for bovine enterovirus, bovine coronavirus, and bovine rotavirus

Frontiers in Veterinary Science, 2023
Bovine enterovirus (BEV), bovine coronavirus (BCoV), and bovine rotavirus (BRV) are still the major worldwide concerns in the health care of cattle, causing serious economic losses in the livestock industry.
Junzhen Chen, Dan Li, Dan Li, Yafang Xu, Zeyu Li, Siqi Ma, Xinyi Liu, Yuanyuan Yuan, Chengyuan Zhang, Qiang Fu, Huijun Shi   +10 more
doaj   +1 more source

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

CNS Oncology, 2019
Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS ...
Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai   +11 more
doaj   +1 more source